C4 Therapeutics, Inc. CCCC

Rank #2139 · Nasdaq · $0.4B market cap

⚠ Going-concern flag — the auditor (KPMG LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

32.4

P/E

-3.5

P/B

1.51

ROE

-42.8%

Op. Margin

-336.1%

Debt Ratio

54%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★☆☆☆

Average

P/E -3.5x, P/B 1.51x. Ranks in the top 58% of the universe.

Profitability ★☆☆☆☆

Poor

ROE -42.8%. Ranks in the top 90% of the universe.

Safety ★★★★☆

Good

Debt ratio 54%. Ranks in the top 25% of the universe.

Growth ★★★★★

Excellent

Revenue growth of 71.4% year over year. Ranks in the top 5% of the universe.

Growth is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2020	–	$-0.0B	$-0.0B	$-0.1B	–	-150
2021	–	$-0.0B	$-0.0B	$-0.1B	–	-150
2022	$0.0B	$-0.1B	$-0.1B	$0.3B	-179.4	42
2023	$0.0B	$-0.1B	$-0.1B	$0.4B	-416.6	36
2024	$0.0B	$-0.1B	$-0.1B	$0.3B	-669.8	45
2025	$0.0B	$-0.1B	$-0.1B	$0.2B	-336.1	54

← See the full screener